Biocure Technology (CURE) Hits New 12-Month Low at $0.30

Biocure Technology (CNSX:CURE) shares hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $0.30 and last traded at $0.30, with a volume of 25500 shares traded. The stock had previously closed at $0.33.

COPYRIGHT VIOLATION WARNING: “Biocure Technology (CURE) Hits New 12-Month Low at $0.30” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at

Biocure Technology Company Profile (CNSX:CURE)

Biocure Technology Inc develops and commercializes biosimilar pharmaceutical products in South Korea. The company is developing Interferon Beta 1b for the treatment of multiple sclerosis; Ranibizumab, a monoclonal antibody fragment for the treatment of macular degeneration, as well as to treat a type of eye problem known as macular edema; and Filgrastim to treat neutropenia, a lack of white blood cells caused by cancer, bone marrow transplant, chemotherapy, or by other conditions.

Featured Article: Why do company’s buyback their stock?

Receive News & Ratings for Biocure Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocure Technology and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit